Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin versus topiramate for weight loss in bipolar disorder patients receiving sodium valproate
IRCT20220206053958N5Phase 4Completed
- Sponsor
- Alborz University of Medical Sciences
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of metformin and topiramate in Overweight, obesity and bipolar disorder (BD) (2 arms), sponsored by Alborz University of Medical Sciences. Primary endpoint: Change in body weight. Started Apr 2026; status: completed.
02
Drugs
metformintopiramate
03
Conditions
Overweightobesitybipolar disorder (BD)
Beyond the preview
Go deeper on IRCT20220206053958N5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220206053958N5.